[en] BACKGROUND/AIMS: Relapses of Crohn's disease are difficult to predict. We assessed the value of serum level of interleukin-6, tumour necrosis factor alpha (TNF-alpha) and soluble TNF receptors as predictors of relapse in quiescent Crohn's disease. PATIENTS/METHODS: Thirty-six patients with inactive Crohn's disease, treated or not, were included. Various clinical and biological parameters, including interleukin-6, TNF-alpha and soluble TNF receptors serum levels were measured at inclusion in the study and the patients were followed clinically for 1 year. The relapse was defined as a Crohn's Disease Activity Index (CDAI) greater than 150 with an increase greater than 100 compared to the inclusion value. We analysed the ability of these parameters to predict relapse in parallel to clinical characteristics and other laboratory parameters. RESULTS: Among the 32 variables tested, interleukin-6 serum level had the greatest ability to predict the time-to-relapse, with 17-fold chance of relapse over a 1-year period for patients with an interleukin-6 serum level greater than 20 pg/ml than for patients with a lower level (P < 0.001). A high serum level of the soluble TNF receptors p55 and p75 also had significant predictive value, in contrast to TNF-alpha serum levels. An interleukin-6 serum level greater than 20 pg/ml and either an acid alpha-1-glycoprotein level greater than 1.1 g/l or a soluble interleukin-2 receptor serum level greater than 95 pM/l were risk factors selected by a stepwise multivariate analysis. In both models a good prognosis group was defined by the absence of the two risk factors, a bad prognostic group by the presence of the two risk factors and an intermediate in between. With both models, the good prognosis group included 17 patients who experienced no relapse over the 1-year follow-up, whereas all patients (seven with the first model and six with the second) in the bad prognosis group had a relapse during the follow-up. Looking specifically at two homogeneous subgroups including either naturally/5-aminosalicylic acid (5-ASA) quiescent or corticoid quiescent patients, a very good predictive value for interleukin-6 serum concentration was also found. CONCLUSION: Interleukin-6 serum level alone or in association with other biological parameters such as acid alpha-1-glycoprotein or the soluble interleukin-2 receptor serum level may be useful for predicting the course of the disease in patients with quiescent Crohn's disease.
Sahmoud T, Hoctin-Boes G, Modigliani R, et al.: Identifying patients with a high risk of relapse in quiescent Crohn's disease. Gut 1995, 37:811-818.
Brignola C, Campieri M, Bazzocchi G, et al.: A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease. Gastroenterology 1986, 91:1490-1494.
Brignola C, Iannone P, Belloli C, et al.: Prediction of relapse in patients with Crohn's disease in remission: a simplified index using laboratory tests, enhanced by clinical characteristics. Eur J Gastroenterol Hepatol 1994, 6:955-961.
Wyatt J, Vogelsgang H, Hübl W, et al.: Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet 1993, 341:1437-1439.
Schreiber S, Raedler A, Stenson WF, et al.: The role of the mucosal immune system in inflammatory bowel disease. Gastroenterol Clin North Am 1992, 21:451-502.
Louis E, Belaiche J, Van Kemseke C, et al.: Soluble interleukin-2 receptor in Crohn's disease: assessment of disease activity and prediction of relapse. Dig Dis Sci 1995, 40:1750-1756.
Gelbmann CM, Barrett KE: Role of inflammatory cell types. In Inflammatory Bowel Disease Pathophysiology as Basis of Treatment. Edited by Schölmerich J, Kruis W, Goebell H, et al. Dordrecht, Boston, London: Kluwer Academic Publishers; 1993:62-79.
Hirano T: Interleukin-6. In The Cytokine Handbook. Edited by Thomson A. London: Academic Press; 1991:169-190.
Manogue KR, Van Deventer SJH, Cerami A: Tumour necrosis factor alpha or cachectin. In The Cytokine Handbook. Edited by Thomson A. London: Academic Press; 1991:241-256.
Breese EJ, Michie CA, Nicchols SW, et al.: Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994, 106:1455-1466.
Reinecker HC, Steffen M, Witthoeft T, et al.: Enhanced secretion of tumour necrosis factor alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993, 94:174-181.
Maeda M, Watanabe N, Neda H, et al.: Serum tumor necrosis factor activity in inflammatory bowel disease. Immunopharmacol Immunotoxicol 1992, 14:451-461.
Gross V, Andus T, Caesar I, et al.: Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterology 1992, 102:514-519.
Hyams JS, Fitzgerald JE, Treem WR, et al.: Relationship of functional and antigenic interleukin 6 to disease activity in inflammatory bowel disease. Gastroenterology 1993, 104:1285-1292.
Louis E, Van Kemseke C, De Groote D, et al.: IL-6, TNF-α and soluble TNF-α receptor serum levels in Crohn's disease [abstract]. Gut 1994, 35(suppl. 4):A22.
Spinas GA, Keller U, Brockhaus M: Release of soluble receptor for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia. J Clin Invest 1992, 90:533-536.
Van Zee KJ, Kohno T, Fischer E, et al.: Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor α in vitro and in vivo. Proc Natl Acad Sci USA 1992, 89:4845-4849.
Best WR, Becktel JM, Singelton JW, et al.: Development of a Crohn's disease activity index: national co-operative Crohn's disease study. Gastroenterology 1976, 70:439-444.
Peto R, Pike MC, Armitage P, et al.: Design and analysis of randomized trials requiring prolonged observations of each patient. Br J Cancer 1977, 35:1-39.
Byar DP: Identification of prognostic factors. In Cancer Clinical Trials. Methods and Practice. Edited by Buyse ME, Staquet MJ, Sylvester RJ. Oxford: Oxford Medical Publications; 1988:423-443.
Cox DR, Oakes D: Analysis of Survival Data. London: Chapman and Hall; 1984.
Kaplan ER, Meier P: Nonparametric estimation for incomplete observations. J Am Statistical Assoc 1956, 53:457-401.
Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966, 50:163-170.
Modigliani R, Mary JY, Simon JF, et al.: Clinical, biological, and endoscopic picture of attacks of Crohn's disease: evolution on prednisolone. Gastroenterology 1990, 99:956-963.
Kusugami K, Fukatsu A, Tanimoto M, et al.: Elevation of interleukin-6 in inflammatory bowel disease is macrophage- and epithelial cell-dependent. Dig Dis Sci 1995, 40:949-959.